Prytime Medical Closes Oversubscribed $6M Inside Funding Round to Fuel Commercialization Growth

The capital will be used to accelerate the commercialization of Prytime Medical's new line of minimally invasive REBOA (Resuscitative Endovascular Balloon Occlusion of the Aorta) hemorrhage control products. SAN ANTONIO, June 2, 2021 -- (Healthcare Sale... Devices, Venture Capital Prytime Medical, REBOA catheter, hemorrhage, truncal hemorrhage
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news